This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Rajiv Tandon, MD
University of Michigan Hospitals Ann Arbor, MI 48109-0120

John M. Kane, MD
Glen Oaks, NY

Arch Gen Psychiatry. 1993;50(2):158-159.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

In comparison with standard neuroleptics, clozapine is more effective in decreasing positive and negative symptoms in treatmentrefractory schizophrenic patients, and causes significantly fewer parkinsonian side effects and less tardive dyskinesia.¹ In recent months, three distinct neurochemical hypotheses to explain clozapine's unique profile have been discussed in the ARCHIVES.^2-4 Farde et al² propose that clozapine's lower D₂ dopamine receptor binding may explain the infrequent extrapyramidal syndromes (EPSs), and its higher D₁ dopamine receptor binding may explain its superior efficacy. Meltzer and Stockmeier³ suggest that clozapine's significant serotonin (5-HT₂) antagonist activity may explain both its unique properties. Pickar et al⁴ propose that clozapine's potent ₂-noradrenergic antagonist activity (in addition to its anti-5-HT₂ activity) may be relevant to its unique profile. Clozapine's greater affinity for the D₄ dopamine receptor site⁵ has been implicated as well. Recent data . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?